Khan FA, et al. - In this retrospective study of individuals with chronic migraine (CM) who received uninterrupted onabotulinumtoxinA (BoNTA) therapy from January 2014 to March 2018, experts explained the demographics of people at baseline and compare groups of individuals with various episodes of wearing off effect (WOE). A total of 98 eligible individuals were recognized and 471 treatment cycles were investigated. It was noted that to alleviate the development of central sensitization is the fundamental goal of BoNTA in the treatment of CM. In all individuals, as the 12-week injection paradigm may not provide maintained antinociceptive impact, it may be considered for the failure of response to BoNTA. Moreover, repeated occurrences of the WOE could possibly result in medication overuse and affect the quality of life.